Journal Article

DZNE-2026-01030

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Comparison of amyloid-β, total tau and phospho-tau in clinical AD patients with and without epileptiform EEG patterns.

Ott, L. R. ; Hermann, W.DZNE* ; Köhling, R. ; Storch, A.DZNE* ; Teipel, S. J.DZNE* ; Kirschstein, T.

2026
Elsevier Science Amsterdam [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/j.eplepsyres.2026.107921

Abstract: Epilepsy is a relevant comorbidity of dementia due to Alzheimer's Disease (AD) and probably directly related to its pathology. We aimed to generate hypotheses how interictal epileptiform discharges (IEDs) may be associated with pathological levels of AD markers from cerebrospinal fluid (CSF).To perform bivariate analyses between IEDs or EEG background slowing to CSF AD markers including amyloid-β42 to amyloid-β40 ratio (Aβ ratio), total tau and phospho-tau.In this retrospective cross-sectional study, we identified 26 clinical AD patients who presented with at least one of three pathological neurodegeneration markers in the CSF (Aβ ratio ≤0.5, total tau ≥370 pg/ml, phospho-tau ≥66 pg/ml) and received at least one routine EEG.IEDs and EEG background slowing were present in 5/26 and 14/26 patients, respectively. We observed that patients with IEDs or EEG background slowing had significantly lower phospho-tau levels than patients without (Cohen's d=0.91, P = 0.044 and Cohen's d=1.33, P = 0.005, respectively). Consistent with this, a positive history of seizures tended to be associated with lower phospho-tau levels (Cohen's d=0.79, P = 0.059). Moreover, phospho-tau levels were significantly correlated to dominant posterior EEG frequencies (Spearman's ρ=0.524, P = 0.006), and Aβ ratios were significantly lower in patients with normal EEG background frequencies than in those with EEG slowing (Cohen's d=1.31, P = 0.017).Our bivariate analyses revealed the unexpected observation that the presence of IEDs was associated with lower rather than higher phospho-tau levels in clinical AD patients. This finding awaits further confirmation in a larger cohort.

Keyword(s): Anti-seizure medication ; Epilepsy ; Phosphorylated tau ; Threonine-181

---

Contributing Institute(s):

1. Non-Motor Symptoms in Parkinson's disease (AG Storch)
2. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---